Research study · The Canadian Journal of Psychiatry · 2026
Changes in Cross-Sectional Associations Between Cannabis Use and Anxiety, Depression, and Suicidality in a Nationally Representative Sample of Canadians From 2012 to 2022: Évolution des relations transversales entre la consommation de cannabis et la dépression, l’anxiété et les idées suicidaires au sein d’un échantillon représentatif de Canadiens à l’échelle nationale, de 2012 à 2022
Verified on PubMed Oxford CEBM Level 2B: Clinical Cohort Study
A 2026 study in The Canadian Journal of Psychiatry tested marijuana use in major depressive disorder. The links between frequent cannabis use and mental health struggles grew significantly stronger over the ten-year period. This study suggests that clinicians should be more vigilant about screening for anxiety, depression, and suicidal thoughts in patients who use cannabis.
In plain language
Study overview
Researchers analyzed two large national health surveys from Canada conducted ten years apart to understand how cannabis use relates to anxiety, depression, and thoughts of suicide over time. They compared how often people used cannabis against whether they experienced these mental health conditions across the entire population, including youth and adults.
Findings
The links between frequent cannabis use and mental health struggles grew significantly stronger over the ten-year period. People who used cannabis multiple times a week were much more likely to report anxiety, depression, and thoughts of suicide in the later survey compared to the earlier one.
Explore Dr. Caplan's interactive tool detailing cytochrome P450 pathways, clinical titration intervals, and physician surveillance rules.
The deeper readScientific analysis
Objective: As epidemiological patterns of cannabis use and internalizing problems evolve globally, it is critical to reassess their associations—particularly in the post-legalization and post-pandemic context. Methods: Participants were assessed in the 2012 Canadian Community Health Survey's Mental Health Component (CCHS-MH; n=25,113) and 2022 Mental Health and Access to Care Survey (MHACS; n=9,861), two nationally representative cross-sectional epidemiologic surveys of Canadians aged 15+. Robust Poisson Regression analyses examined associations between frequency of cannabis use and past 12-month generalized anxiety disorder (GAD), major depressive episode (MDE), and suicidality assessed using the World Health Organization Composite International Diagnostic Interview. Results: Between 2012 and 2022, the prevalence of GAD, MDE, and cannabis use (any and 2+/week) approximately doubled, while suicidality remained unchanged in the full sample but increased by 44% among youth. Across all models, cannabis frequency was consistently associated with a higher prevalence of GAD, MDE, and suicidality in a frequency-dependent fashion. Additive interactions between year and cannabis on each of the outcomes demonstrated stronger associations in 2022 versus 2012. For example, from 2012 to 2022, those using cannabis 2+/week (relative to no use) had a: (1) prevalence ratio (PR) for GAD of 2.3 (95% CI, 1.6-3.4) increase to 4.5 (3.8-5.2); (2) prevalence ratio (PR) for MDE of 3.0 (2.3-3.9) increase to 5.2 (4.6-5.7); and (3) prevalence ratio (PR) for suicidality of 3.0 (2.1-4.0) increase to 5.4 (4.7-6.1). Select moderation effects indicated associations between cannabis and MDE or suicidality strengthened more among youth (15-24 vs. 25+), and associations with GAD strengthened more among females.
The paper
Citation
Halladay J, Ji C, Georgiades K, McDonald A, Sunderland M, Slade T, et al. Changes in Cross-Sectional Associations Between Cannabis Use and Anxiety, Depression, and Suicidality in a Nationally Representative Sample of Canadians From 2012 to 2022: Évolution des relations transversales entre la consommation de cannabis et la dépression, l’anxiété et les idées suicidaires au sein d’un échantillon représentatif de Canadiens à l’échelle nationale, de 2012 à 2022. The Canadian Journal of Psychiatry (2026). PubMed 41746129 · DOI
Limitations the authors noted
Data are derived from repeated cross-sectional surveys, precluding causal inferences. Different data collection methodologies were used between 2012 (mostly in-person) and 2022 (entirely telephone-based due to the pandemic), with lower response rates in 2022. Cannabis use was assessed using coarse frequency measures rather than gold-standard timeline follow-back methods or detailed potency/quantity metrics. Potential for residual and unmeasured confounding despite adjustment for sociodemographic factors and substance use covariates.
In practice
Why this matters
This study suggests that clinicians should be more vigilant about screening for anxiety, depression, and suicidal thoughts in patients who use cannabis frequently, as the link between these issues appears to have strengthened over the last decade.
Frequently asked questions
Clinical Questions & Answers
What were the primary clinical findings regarding Marijuana use and Major depressive disorder?
The links between frequent cannabis use and mental health struggles grew significantly stronger over the ten-year period. People who used cannabis multiple times a week were much more likely to report anxiety, depression, and thoughts of suicide in the later survey compared to the earlier one.
What study limitations or clinical safeguards should patients keep in mind?
Data are derived from repeated cross-sectional surveys, precluding causal inferences. Different data collection methodologies were used between 2012 (mostly in-person) and 2022 (entirely telephone-based due to the pandemic), with lower response rates in 2022. Cannabis use was assessed usin...
Browse related research
Condition: Major depressive disorder Condition: Suicide Topic: Marijuana use
Related on CED Clinic
Back to Daily Research and Patient Questions
Reviewed by Dr. Caplan on October 29, 2026.
This page is general education about a published study. It is not medical advice and does not create a doctor-patient relationship. For care specific to you, book a consultation.